The global market for Influenza Vaccination was valued at US$ 9135 million in the year 2024 and is projected to reach a revised size of US$ 13501 million by 2031, growing at a CAGR of 5.5% during the forecast period.

Influenza Vaccination Market

Influenza vaccination is the public-health intervention of administering approved influenza vaccines to individuals—seasonally or by risk-based strategies—to establish immunity against circulating influenza strains, thereby reducing infection rates, severe disease, and healthcare burden. Vaccination is delivered across community, clinical, school, and corporate settings and can utilize inactivated, live-attenuated, recombinant-protein, or emerging mRNA/genetic platforms. Beyond reducing individual disease, influenza vaccination mitigates healthcare-system strain during seasonal peaks, preserves workforce and service continuity among key populations, and reduces broader economic impacts—delivering measurable public and commercial returns for governments, corporations, and insurers. Recent platform innovation, diversified delivery channels, and regulatory streamlining are shifting vaccination from a one-off public-health measure to a routine, value-bearing service.In 2024, global Influenza vaccination production reached approximately 845.8 m units, with an average global market price of around US$ 10.8 perunit.The average gross profit margin of this product is 56%.

Influenza vaccination is in a transitional window from being a “seasonal public-health tool” to becoming a component of routine health management and organizational risk mitigation. Governments, insurers, and corporate risk managers increasingly prioritize vaccination to reduce healthcare system strain during seasonal peaks, creating durable policy and procurement support. Major vaccine manufacturers’ annual reports highlight platform upgrades— including recombinant and mRNA approaches—faster formulation updating, and measures to broaden access; these enhancements enable more responsive value chains that can better match circulating strains and support higher product and service value. Regulatory improvements aimed at preparedness and international collaboration are also enhancing institutional support for cross-border supply and R&D partnerships. For companies and investors, this is an opportunity to embed vaccination into corporate health programs, insurance product design, and long-term public procurement strategies.

Despite clear opportunities, the industry faces systemic risks: viral antigenic drift and the uncertainty of strain-vaccine matching demand high flexibility in R&D and manufacturing release cycles; vaccination uptake remains sensitive to public awareness, payment mechanisms, and access, causing demand variability in some regions; dependence on specific upstream materials and production assets means that regional policy or logistics disruptions can impact capacity; and the rapid market entry of new technology platforms alters competitive dynamics, forcing incumbents to sustain investment in capital and production upgrades. Annual reports frequently warn of market volatility, regulatory heterogeneity, and the complexity of managing diverse distribution channels—factors that require measured expansion strategies.

Demand is shifting from purely seasonal vaccination toward structured, routine immunization programs focused on high-risk groups and institutional delivery. Hospitals, long-term care facilities, schools, and large employers increasingly incorporate influenza vaccination into annual health plans or employee benefits, favoring centralized procurement and mass-vaccination approaches. The expansion of community vaccination sites, pharmacy-based services, mobile clinics, and digital scheduling systems is improving accessibility and uptake. Consumer preference for higher-efficacy products and lower reactogenicity is accelerating penetration of quadrivalent, high-dose, or adjuvanted vaccines. Corporate annual reports and government communications alike indicate that service convenience, scenario-based delivery, and product differentiation are the three principal factors driving downstream willingness to pay.

Upstream inputs include seed viruses or expression vectors, cell substrates or egg-based matrices and specialized culture systems, adjuvant formulations, and sterile-filling consumables—forming a supply landscape characterized by high technical requirements and relative concentration. Annual reports show that advanced platforms demand greater purity, consistency, and traceability from raw materials, raising the technical threshold for supply-chain management and making upstream suppliers strategic partners. As multiple production platforms coexist, upstream differentiation will directly influence process efficiency, capacity scalability, and cost structure. Cold-chain packaging and quality-control reagents are also critical upstream elements, and their reliability and compliance are essential for cross-border supply and large-scale campaigns. Companies commonly emphasize strategic procurement, supplier diversification, and long-term contracts to mitigate upstream risk.

This report aims to provide a comprehensive presentation of the global market for Influenza Vaccination, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Influenza Vaccination.

The Influenza Vaccination market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Influenza Vaccination market comprehensively. Regional market sizes, concerning products by Type, by Application, by Technology and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Influenza Vaccination companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Influenza Vaccination Market Report

Report Metric	Details
Report Name	Influenza Vaccination Market
Accounted market size in year	US$ 9135 million
Forecasted market size in 2031	US$ 13501 million
CAGR	5.5%
Base Year	year
Forecasted years	2026 - 2031
Segment by Type	Trivalent Influenza Vaccine Quadrivalent Influenza Vaccine
Segment by Technology	Chicken Embryo Technology Cell Culture Technology Recombinant Technology Adjuvant Vaccines
Segment by Administration	Injectable Nasal Spray
Segment by Application	6 Months to 3 Years > 3 Years
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Sanofi, CSL, GSK, Viatris, AstraZeneca, Hualan Bio, Changchun Institute of Biological, Sinovac, BCHT, Jiangsu GDK, KM Biologics
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, by Technology etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Influenza Vaccination company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Influenza Vaccination Market growing?

Ans: The Influenza Vaccination Market witnessing a CAGR of 5.5% during the forecast period 2026-2031.

What is the Influenza Vaccination Market size in 2031?

Ans: The Influenza Vaccination Market size in 2031 will be US$ 13501 million.

Who are the main players in the Influenza Vaccination Market report?

Ans: The main players in the Influenza Vaccination Market are Sanofi, CSL, GSK, Viatris, AstraZeneca, Hualan Bio, Changchun Institute of Biological, Sinovac, BCHT, Jiangsu GDK, KM Biologics

What are the Application segmentation covered in the Influenza Vaccination Market report?

Ans: The Applications covered in the Influenza Vaccination Market report are 6 Months to 3 Years, > 3 Years

What are the Type segmentation covered in the Influenza Vaccination Market report?

Ans: The Types covered in the Influenza Vaccination Market report are Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Influenza Vaccination Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Trivalent Influenza Vaccine

1.2.3 Quadrivalent Influenza Vaccine

1.3 Market by Technology

1.3.1 Global Influenza Vaccination Market Size Growth Rate by Technology: 2020 VS 2024 VS 2031

1.3.2 Chicken Embryo Technology

1.3.3 Cell Culture Technology

1.3.4 Recombinant Technology

1.3.5 Adjuvant Vaccines

1.4 Market by Administration

1.4.1 Global Influenza Vaccination Market Size Growth Rate by Administration: 2020 VS 2024 VS 2031

1.4.2 Injectable

1.4.3 Nasal Spray

1.5 Market by Application

1.5.1 Global Influenza Vaccination Market Growth by Application: 2020 VS 2024 VS 2031

1.5.2 6 Months to 3 Years

1.5.3 > 3 Years

1.6 Assumptions and Limitations

1.7 Study Objectives

1.8 Years Considered

2 Global Growth Trends

2.1 Global Influenza Vaccination Market Perspective (2020-2031)

2.2 Global Influenza Vaccination Growth Trends by Region

2.2.1 Global Influenza Vaccination Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Influenza Vaccination Historic Market Size by Region (2020-2025)

2.2.3 Influenza Vaccination Forecasted Market Size by Region (2026-2031)

2.3 Influenza Vaccination Market Dynamics

2.3.1 Influenza Vaccination Industry Trends

2.3.2 Influenza Vaccination Market Drivers

2.3.3 Influenza Vaccination Market Challenges

2.3.4 Influenza Vaccination Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Influenza Vaccination Players by Revenue

3.1.1 Global Top Influenza Vaccination Players by Revenue (2020-2025)

3.1.2 Global Influenza Vaccination Revenue Market Share by Players (2020-2025)

3.2 Global Top Influenza Vaccination Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Influenza Vaccination Revenue

3.4 Global Influenza Vaccination Market Concentration Ratio

3.4.1 Global Influenza Vaccination Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Influenza Vaccination Revenue in 2024

3.5 Global Key Players of Influenza Vaccination Head office and Area Served

3.6 Global Key Players of Influenza Vaccination, Product and Application

3.7 Global Key Players of Influenza Vaccination, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Influenza Vaccination Breakdown Data by Type

4.1 Global Influenza Vaccination Historic Market Size by Type (2020-2025)

4.2 Global Influenza Vaccination Forecasted Market Size by Type (2026-2031)

5 Influenza Vaccination Breakdown Data by Application

5.1 Global Influenza Vaccination Historic Market Size by Application (2020-2025)

5.2 Global Influenza Vaccination Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Influenza Vaccination Market Size (2020-2031)

6.2 North America Influenza Vaccination Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Influenza Vaccination Market Size by Country (2020-2025)

6.4 North America Influenza Vaccination Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Influenza Vaccination Market Size (2020-2031)

7.2 Europe Influenza Vaccination Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Influenza Vaccination Market Size by Country (2020-2025)

7.4 Europe Influenza Vaccination Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Influenza Vaccination Market Size (2020-2031)

8.2 Asia-Pacific Influenza Vaccination Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Influenza Vaccination Market Size by Region (2020-2025)

8.4 Asia-Pacific Influenza Vaccination Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Influenza Vaccination Market Size (2020-2031)

9.2 Latin America Influenza Vaccination Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Influenza Vaccination Market Size by Country (2020-2025)

9.4 Latin America Influenza Vaccination Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Influenza Vaccination Market Size (2020-2031)

10.2 Middle East & Africa Influenza Vaccination Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Influenza Vaccination Market Size by Country (2020-2025)

10.4 Middle East & Africa Influenza Vaccination Market Size by Country (2026-2031)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Sanofi

11.1.1 Sanofi Company Details

11.1.2 Sanofi Business Overview

11.1.3 Sanofi Influenza Vaccination Introduction

11.1.4 Sanofi Revenue in Influenza Vaccination Business (2020-2025)

11.1.5 Sanofi Recent Development

11.2 CSL

11.2.1 CSL Company Details

11.2.2 CSL Business Overview

11.2.3 CSL Influenza Vaccination Introduction

11.2.4 CSL Revenue in Influenza Vaccination Business (2020-2025)

11.2.5 CSL Recent Development

11.3 GSK

11.3.1 GSK Company Details

11.3.2 GSK Business Overview

11.3.3 GSK Influenza Vaccination Introduction

11.3.4 GSK Revenue in Influenza Vaccination Business (2020-2025)

11.3.5 GSK Recent Development

11.4 Viatris

11.4.1 Viatris Company Details

11.4.2 Viatris Business Overview

11.4.3 Viatris Influenza Vaccination Introduction

11.4.4 Viatris Revenue in Influenza Vaccination Business (2020-2025)

11.4.5 Viatris Recent Development

11.5 AstraZeneca

11.5.1 AstraZeneca Company Details

11.5.2 AstraZeneca Business Overview

11.5.3 AstraZeneca Influenza Vaccination Introduction

11.5.4 AstraZeneca Revenue in Influenza Vaccination Business (2020-2025)

11.5.5 AstraZeneca Recent Development

11.6 Hualan Bio

11.6.1 Hualan Bio Company Details

11.6.2 Hualan Bio Business Overview

11.6.3 Hualan Bio Influenza Vaccination Introduction

11.6.4 Hualan Bio Revenue in Influenza Vaccination Business (2020-2025)

11.6.5 Hualan Bio Recent Development

11.7 Changchun Institute of Biological

11.7.1 Changchun Institute of Biological Company Details

11.7.2 Changchun Institute of Biological Business Overview

11.7.3 Changchun Institute of Biological Influenza Vaccination Introduction

11.7.4 Changchun Institute of Biological Revenue in Influenza Vaccination Business (2020-2025)

11.7.5 Changchun Institute of Biological Recent Development

11.8 Sinovac

11.8.1 Sinovac Company Details

11.8.2 Sinovac Business Overview

11.8.3 Sinovac Influenza Vaccination Introduction

11.8.4 Sinovac Revenue in Influenza Vaccination Business (2020-2025)

11.8.5 Sinovac Recent Development

11.9 BCHT

11.9.1 BCHT Company Details

11.9.2 BCHT Business Overview

11.9.3 BCHT Influenza Vaccination Introduction

11.9.4 BCHT Revenue in Influenza Vaccination Business (2020-2025)

11.9.5 BCHT Recent Development

11.10 Jiangsu GDK

11.10.1 Jiangsu GDK Company Details

11.10.2 Jiangsu GDK Business Overview

11.10.3 Jiangsu GDK Influenza Vaccination Introduction

11.10.4 Jiangsu GDK Revenue in Influenza Vaccination Business (2020-2025)

11.10.5 Jiangsu GDK Recent Development

11.11 KM Biologics

11.11.1 KM Biologics Company Details

11.11.2 KM Biologics Business Overview

11.11.3 KM Biologics Influenza Vaccination Introduction

11.11.4 KM Biologics Revenue in Influenza Vaccination Business (2020-2025)

11.11.5 KM Biologics Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Changchun Institute of Biological

List of Tables

Table 1. Global Influenza Vaccination Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Trivalent Influenza Vaccine

Table 3. Key Players of Quadrivalent Influenza Vaccine

Table 4. Global Influenza Vaccination Market Size Growth Rate by Technology (US$ Million): 2020 VS 2024 VS 2031

Table 5. Key Players of Chicken Embryo Technology

Table 6. Key Players of Cell Culture Technology

Table 7. Key Players of Recombinant Technology

Table 8. Key Players of Adjuvant Vaccines

Table 9. Global Influenza Vaccination Market Size Growth Rate by Administration (US$ Million): 2020 VS 2024 VS 2031

Table 10. Key Players of Injectable

Table 11. Key Players of Nasal Spray

Table 12. Global Influenza Vaccination Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 13. Global Influenza Vaccination Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 14. Global Influenza Vaccination Market Size by Region (2020-2025) & (US$ Million)

Table 15. Global Influenza Vaccination Market Share by Region (2020-2025)

Table 16. Global Influenza Vaccination Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 17. Global Influenza Vaccination Market Share by Region (2026-2031)

Table 18. Influenza Vaccination Market Trends

Table 19. Influenza Vaccination Market Drivers

Table 20. Influenza Vaccination Market Challenges

Table 21. Influenza Vaccination Market Restraints

Table 22. Global Influenza Vaccination Revenue by Players (2020-2025) & (US$ Million)

Table 23. Global Influenza Vaccination Market Share by Players (2020-2025)

Table 24. Global Top Influenza Vaccination Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Vaccination as of 2024)

Table 25. Ranking of Global Top Influenza Vaccination Companies by Revenue (US$ Million) in 2024

Table 26. Global 5 Largest Players Market Share by Influenza Vaccination Revenue (CR5 and HHI) & (2020-2025)

Table 27. Global Key Players of Influenza Vaccination, Headquarters and Area Served

Table 28. Global Key Players of Influenza Vaccination, Product and Application

Table 29. Global Key Players of Influenza Vaccination, Date of Enter into This Industry

Table 30. Mergers & Acquisitions, Expansion Plans

Table 31. Global Influenza Vaccination Market Size by Type (2020-2025) & (US$ Million)

Table 32. Global Influenza Vaccination Revenue Market Share by Type (2020-2025)

Table 33. Global Influenza Vaccination Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 34. Global Influenza Vaccination Revenue Market Share by Type (2026-2031)

Table 35. Global Influenza Vaccination Market Size by Application (2020-2025) & (US$ Million)

Table 36. Global Influenza Vaccination Revenue Market Share by Application (2020-2025)

Table 37. Global Influenza Vaccination Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 38. Global Influenza Vaccination Revenue Market Share by Application (2026-2031)

Table 39. North America Influenza Vaccination Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 40. North America Influenza Vaccination Market Size by Country (2020-2025) & (US$ Million)

Table 41. North America Influenza Vaccination Market Size by Country (2026-2031) & (US$ Million)

Table 42. Europe Influenza Vaccination Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Europe Influenza Vaccination Market Size by Country (2020-2025) & (US$ Million)

Table 44. Europe Influenza Vaccination Market Size by Country (2026-2031) & (US$ Million)

Table 45. Asia-Pacific Influenza Vaccination Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 46. Asia-Pacific Influenza Vaccination Market Size by Region (2020-2025) & (US$ Million)

Table 47. Asia-Pacific Influenza Vaccination Market Size by Region (2026-2031) & (US$ Million)

Table 48. Latin America Influenza Vaccination Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 49. Latin America Influenza Vaccination Market Size by Country (2020-2025) & (US$ Million)

Table 50. Latin America Influenza Vaccination Market Size by Country (2026-2031) & (US$ Million)

Table 51. Middle East & Africa Influenza Vaccination Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 52. Middle East & Africa Influenza Vaccination Market Size by Country (2020-2025) & (US$ Million)

Table 53. Middle East & Africa Influenza Vaccination Market Size by Country (2026-2031) & (US$ Million)

Table 54. Sanofi Company Details

Table 55. Sanofi Business Overview

Table 56. Sanofi Influenza Vaccination Product

Table 57. Sanofi Revenue in Influenza Vaccination Business (2020-2025) & (US$ Million)

Table 58. Sanofi Recent Development

Table 59. CSL Company Details

Table 60. CSL Business Overview

Table 61. CSL Influenza Vaccination Product

Table 62. CSL Revenue in Influenza Vaccination Business (2020-2025) & (US$ Million)

Table 63. CSL Recent Development

Table 64. GSK Company Details

Table 65. GSK Business Overview

Table 66. GSK Influenza Vaccination Product

Table 67. GSK Revenue in Influenza Vaccination Business (2020-2025) & (US$ Million)

Table 68. GSK Recent Development

Table 69. Viatris Company Details

Table 70. Viatris Business Overview

Table 71. Viatris Influenza Vaccination Product

Table 72. Viatris Revenue in Influenza Vaccination Business (2020-2025) & (US$ Million)

Table 73. Viatris Recent Development

Table 74. AstraZeneca Company Details

Table 75. AstraZeneca Business Overview

Table 76. AstraZeneca Influenza Vaccination Product

Table 77. AstraZeneca Revenue in Influenza Vaccination Business (2020-2025) & (US$ Million)

Table 78. AstraZeneca Recent Development

Table 79. Hualan Bio Company Details

Table 80. Hualan Bio Business Overview

Table 81. Hualan Bio Influenza Vaccination Product

Table 82. Hualan Bio Revenue in Influenza Vaccination Business (2020-2025) & (US$ Million)

Table 83. Hualan Bio Recent Development

Table 84. Changchun Institute of Biological Company Details

Table 85. Changchun Institute of Biological Business Overview

Table 86. Changchun Institute of Biological Influenza Vaccination Product

Table 87. Changchun Institute of Biological Revenue in Influenza Vaccination Business (2020-2025) & (US$ Million)

Table 88. Changchun Institute of Biological Recent Development

Table 89. Sinovac Company Details

Table 90. Sinovac Business Overview

Table 91. Sinovac Influenza Vaccination Product

Table 92. Sinovac Revenue in Influenza Vaccination Business (2020-2025) & (US$ Million)

Table 93. Sinovac Recent Development

Table 94. BCHT Company Details

Table 95. BCHT Business Overview

Table 96. BCHT Influenza Vaccination Product

Table 97. BCHT Revenue in Influenza Vaccination Business (2020-2025) & (US$ Million)

Table 98. BCHT Recent Development

Table 99. Jiangsu GDK Company Details

Table 100. Jiangsu GDK Business Overview

Table 101. Jiangsu GDK Influenza Vaccination Product

Table 102. Jiangsu GDK Revenue in Influenza Vaccination Business (2020-2025) & (US$ Million)

Table 103. Jiangsu GDK Recent Development

Table 104. KM Biologics Company Details

Table 105. KM Biologics Business Overview

Table 106. KM Biologics Influenza Vaccination Product

Table 107. KM Biologics Revenue in Influenza Vaccination Business (2020-2025) & (US$ Million)

Table 108. KM Biologics Recent Development

Table 109. Research Programs/Design for This Report

Table 110. Key Data Information from Secondary Sources

Table 111. Key Data Information from Primary Sources

Table 112. Authors List of This Report

List of Figures

Figure 1. Influenza Vaccination Picture

Figure 2. Global Influenza Vaccination Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Influenza Vaccination Market Share by Type: 2024 VS 2031

Figure 4. Trivalent Influenza Vaccine Features

Figure 5. Quadrivalent Influenza Vaccine Features

Figure 6. Global Influenza Vaccination Market Size Comparison by Technology (2020-2031) & (US$ Million)

Figure 7. Chicken Embryo Technology Features

Figure 8. Cell Culture Technology Features

Figure 9. Recombinant Technology Features

Figure 10. Adjuvant Vaccines Features

Figure 11. Global Influenza Vaccination Market Size Comparison by Administration (2020-2031) & (US$ Million)

Figure 12. Injectable Features

Figure 13. Nasal Spray Features

Figure 14. Global Influenza Vaccination Market Size by Application (2020-2031) & (US$ Million)

Figure 15. Global Influenza Vaccination Market Share by Application: 2024 VS 2031

Figure 16. 6 Months to 3 Years Case Studies

Figure 17. > 3 Years Case Studies

Figure 18. Influenza Vaccination Report Years Considered

Figure 19. Global Influenza Vaccination Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 20. Global Influenza Vaccination Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 21. Global Influenza Vaccination Market Share by Region: 2024 VS 2031

Figure 22. Global Influenza Vaccination Market Share by Players in 2024

Figure 23. Global Influenza Vaccination Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 24. The Top 10 and 5 Players Market Share by Influenza Vaccination Revenue in 2024

Figure 25. North America Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. North America Influenza Vaccination Market Share by Country (2020-2031)

Figure 27. United States Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Canada Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Europe Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Europe Influenza Vaccination Market Share by Country (2020-2031)

Figure 31. Germany Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. France Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. U.K. Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Italy Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Russia Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Ireland Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Asia-Pacific Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Asia-Pacific Influenza Vaccination Market Share by Region (2020-2031)

Figure 39. China Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Japan Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. South Korea Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Southeast Asia Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. India Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Australia & New Zealand Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Latin America Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Latin America Influenza Vaccination Market Share by Country (2020-2031)

Figure 47. Mexico Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Brazil Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Middle East & Africa Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Middle East & Africa Influenza Vaccination Market Share by Country (2020-2031)

Figure 51. Israel Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 52. Saudi Arabia Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 53. UAE Influenza Vaccination Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 54. Sanofi Revenue Growth Rate in Influenza Vaccination Business (2020-2025)

Figure 55. CSL Revenue Growth Rate in Influenza Vaccination Business (2020-2025)

Figure 56. GSK Revenue Growth Rate in Influenza Vaccination Business (2020-2025)

Figure 57. Viatris Revenue Growth Rate in Influenza Vaccination Business (2020-2025)

Figure 58. AstraZeneca Revenue Growth Rate in Influenza Vaccination Business (2020-2025)

Figure 59. Hualan Bio Revenue Growth Rate in Influenza Vaccination Business (2020-2025)

Figure 60. Changchun Institute of Biological Revenue Growth Rate in Influenza Vaccination Business (2020-2025)

Figure 61. Sinovac Revenue Growth Rate in Influenza Vaccination Business (2020-2025)

Figure 62. BCHT Revenue Growth Rate in Influenza Vaccination Business (2020-2025)

Figure 63. Jiangsu GDK Revenue Growth Rate in Influenza Vaccination Business (2020-2025)

Figure 64. KM Biologics Revenue Growth Rate in Influenza Vaccination Business (2020-2025)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions